Colon cancer
Conditions
Interventions
Sponsors
Oncology Department, Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with colon cancer confirmed by histopathology or cytopathology; 2. Patients who have undergone radical surgery and whose postoperative pathological stage is stage III and T4 or N2 (according to NCCN clinical practice guideline colorectal cancer (2018 V4) standard); 3. Adjuvant chemotherapy has been completed (for example, 4-8 XELOX, 6-12 FOLFOX, or fluorouracil single drug chemotherapy has been completed, and no adjuvant chemotherapy will be accepted in the near future); 4. The patients without recurrence and metastasis were reexamined in the past 1 month; 5. Patients whose last chemotherapy time was less than 3 months; 6. Patients with PS score (ECoG) = 60ml / min; Normal liver function: total serum bilirubin level <= 1.5 times of upper limit of normal value (ULN), serum AST and ALT 2.5 times of ULN; 9. The patients who sign the informed consent and are willing to receive the treatment of this program, can insist on taking medicine and have good compliance.
Exclusion criteria
Exclusion criteria: 1. Patients who are unable to complete the baseline assessment form; 2. Patients with ileus or incomplete ileus; 3. Patients with other serious diseases, including uncontrolled active infection, severe electrolyte disorder, and obvious bleeding tendency; 4. Pregnant and lactating women; 5. Patients with autoimmune diseases and blood system diseases, or long-term use of hormone or immunosuppressant; 6. Patients with other uncontrolled tumors; 7. Patients who have received new adjuvant or adjuvant radiotherapy, or intend to receive radiotherapy; 8. Patients with serious brain disease or mental disease that affect the ability of self-report; 9. Have a history of organ transplantation (including bone marrow autotransplantation and peripheral stem cell transplantation); 10. Patients without legal capacity, and those who are affected by medical or ethical reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3 year recurrence and metastasis rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 1 year recurrence and metastasis rate;2 year recurrence and metastasis rate; | — |
Countries
China
Contacts
Public ContactHaibo Zhang
Guangdong Provincial Hospital of Traditional Chinese Medicine
Outcome results
None listed